Definition: Irreversible formation of fibrosis, restricting hepatic cell regeneration, forming nodules of poorly-functioning cells.
Ultrasound Findings: Nodular/shrunken liver.
Transient Elastography: Increased liver stiffness.
Biopsy Findings: Diffuse fibrosis with nodular regeneration.
Impact on Blood Flow: Fibrotic liver increases resistance to blood flow leading to:
Portal Hypertension: Increased pressure in portal venous circulation.
Portosystemic Shunts: Increased flow to esophageal, rectal, and splenic veins resulting in:
Varices: Dilated veins in the esophagus, stomach, or rectum.
Variceal Bleed: Caused by vascular stretching and endothelial vasodilator release (e.g., NO).
Inflammation and Genetic Changes: Inflammation can lead to epigenetic changes, including oncogene mutations, contributing to malignancies like hepatocellular carcinoma.
Indicators: Increased serum alpha-fetoprotein (sensitivity 50%, specificity 99%).
Blood Flow Dynamics: Backflow of blood into the spleen and altered blood flow to kidneys can lead to:
Hypotension: Due to increased vasodilators entering systemic circulation.
Splenomegaly: Enlarged spleen due to increased hydrostatic pressure and sequestration of blood cells.
Hepatopulmonary Syndrome: Rare syndrome due to decreased sonication time for gas exchange in pulmonary vasculature.
Clinical Manifestations of Cirrhosis:
Cytopenias: Risk of thrombocytopenia, anemia, and associated petechiae/bruising.
Hepatic Insufficiency:
Decreased liver synthetic functions affecting clotting factors and anticoagulants leading to:
Unpredictable hemostatic imbalance evidenced by elevated INR.
Ascites: Fluid accumulation in the peritoneal cavity.
Peripheral Edema: Due to fluid retention and hypoalbuminemia.
Toxin Management Failures: Impaired metabolism of metabolites like ammonia, leading to:
Hepatic Encephalopathy: Accumulation leads to neuropsychological symptoms, day-night reversal, asterixis, and delirium.
Bilirubin Management Issues: Reduced conjugation and secretion causing:
Jaundice: Serum bilirubin >30 μmol/L, with scleral icterus and jaundiced frenulum.
Disorders related to swallowing, gastric emptying, ulcer disease, and overall liver function including detoxification leading to jaundice and portal hypertension.
Etiology: Multiple causes including cirrhosis, intra- or extra-hepatic cholestasis, toxins (e.g., CCl4, mushrooms, alcohol).
Precipitating Factors:
High protein intake, infections, TIPS, GI bleed, AKI, and electrolyte derangements can exacerbate HE.
Normal Pathway: Ammonia from protein metabolism is converted to urea via the urea cycle in the liver.
Disruption of Ammonia Management:
Shunting of ammonia bypasses the liver leading to increased levels in the brain.
Elevated ammonia provokes brain edema and neurotransmitter alterations, contributing to neuronal dysfunction.
Increased BBB Permeability: Leads to non-specific elevation due to various metabolites and neurotoxins like GABA and aromatic acids.
Altered Neurotransmissive Mechanisms: Increased production of false neurotransmitters and shifts in neurotransmitter activity, contributing to excitotoxicity and neuronal damage.
GABA Hypothesis: Suggests increased GABAergic tone in the brain could be linked to the pathophysiology of HE.
Grades of HE:
Grade I: Mild altered sleep patterns, decreased attention span.
Grade II: Asterixis, disorientation.
Grade III: Hyperactive reflexes, stupor.
Grade IV: Coma status indicating severe dysfunction.
Portal Hypertension Consequences:
Ascites, increased risk for spontaneous bacterial peritonitis, potential sepsis, varices, splenomegaly, and thrombocytopenia.
Liver Cell Failure Effects:
Jaundice, coagulopathy, hepatic coma, and hyperestrogenemia, resulting in various systemic complications such as hematemesis and ascites.
Other Complications of Cirrhosis:
Hepatorenal syndrome, hepatocellular carcinoma, and hepatopulmonary syndrome.